NULIBRY is a first-in-class synthetic cPMP substrate replacement therapy to reduce the risk of mortality in patients with MoCD Type A
Natco Pharma intends to defend the matter accordingly
Submission based on results from pivotal phase III trial showing all primary endpoints met
SELARSDI is approved for both adult and pediatric indications and is the second biosimilar approved under the strategic partnership between Alvotech and Teva
This acquisition enables MTD to open new, strategic markets
The company had earlier announced about the approval received from the MHRA for Liraglutide
The facility will manufacture tablets, capsules, and injections for the oncology segment
Liraglutide is a drug-device combination formulation used in the treatment of Type 2 Diabetes Mellitus
WINREVAIR is a breakthrough biologic for this rare, progressive disease
CRESEMBA receives seven years and six months of US market exclusivity for these pediatric indications
Subscribe To Our Newsletter & Stay Updated
